Background: The use of intraoperative opioids may influence the rate of postoperative complications. This study evaluated the association between intraoperative opioid dose and the risk of 30-day hospital readmission. Methods: We conducted a pre-specified analysis of existing registry data for 153 902 surgical cases performed under general anaesthesia at Massachusetts General Hospital and two affiliated medical centres. We examined the association between total intraoperative opioid dose (categorised in quintiles) and 30-day hospital readmission, controlling for several patient-, anaesthetist-, and case-specific factors. Results: Compared with low intraoperative opioid dosing [quintile 1, median (inter-quartile range): 8 (4e9) mg morphine equivalents], exposure to high-dose opioids during surgery [quintile 5: 32 (27e41) equivalents] is an independent predictor of 30-day readmission [odds ratio (OR) 1.15 (95% confidence interval 1.07e1.24); P<0.001]. Ambulatory surgery patients receiving high opioid doses were found to have the greatest adjusted risk of readmission (OR 1.75; P<0.001) with a clear doseeresponse effect across quintiles (P for trend <0.05), and were more likely to be readmitted early (postoperative days 0e2 vs 3e30; P<0.001). Opioid class modified the association between total opioid dose and readmission, with longer-acting opioids demonstrating a stronger influence (P<0.001). We observed significant practice variability across individual anaesthetists in the utilisation of opioids that could not be explained by patient-and case-specific factors.
It is important to understand the factors that contribute to readmission after surgery. This study used routinely collected healthcare data to explore the effect of intraoperative opioid on readmission rates. Higher intraoperative opioid doses were associated with an increased risk of readmission. Readmission was not affected by preoperative opioid, but was increased by anaesthetist factors. The reasons for this need to be explored further, with consideration given to using standardised guidelines.
The Centers for Disease Control and Prevention reports a rapid increase in the use of prescription and non-prescription opioid drugs in the United States and Canada in the 2010s, leading to a spike in overuse deaths. Nearly half of all opioid overdose deaths in 2016 involved prescriptions. 1 In Massachusetts, in 2016, there were 1990 opioid-related overdose deathsda 46% increase since 2014, according to the Massachusetts Department of Public Health. 2 This demonstrates the dangers of the recent development of opioid overuse in the general medical context in the United States. During surgery, opioids are widely used to supplement general anaesthetic agents and are the most commonly used analgesic medications for acute surgical pain. 3, 4 Despite their advantages, the adverse effects of acute opioid administration are significant and include respiratory depression, ileus, nausea and vomiting, and hyperalgesia. 5e8 In addition to these well-described short-term side-effects, the potential for perioperative opioid exposure to influence longer-term outcomes has also been demonstrated: a recent study of abdominopelvic operations found preoperative opioid use to be associated with postoperative complications and increased healthcare resource utilisation. 9 These factors and broader public concern regarding the perioperative use of opioid medications 10 have resulted in the emergence of opioid-sparing anaesthetic techniques as alternative approaches to achieving analgesia and 'balanced anaesthesia' with reduced reliance on opioids. 11, 12 Despite the many potential effects of perioperative opioid exposure on postoperative outcomes, relatively little is known about the contribution of the intraoperative component of opioid administration. We sought to quantify the association between intraoperative opioid dose and 30-day hospital readmission (a common quality metric and general indicator of postoperative complications) in a diverse population of surgical patients. We also planned sensitivity analyses to assess the influences of ambulatory surgery status and opioid class on this relationship.
Methods

Study design and setting
We performed a pre-specified analysis of hospital registry data for patients undergoing surgery with general anaesthesia at Massachusetts General Hospital (MGH) and two affiliated community hospitals between January 2007 and December 2015. The study was approved by the Partners Institutional Review Board (protocol number 2015P002586) and was performed in a pre-specified fashion with a defined analytic plan. A strengthening the reporting of observational studies in epidemiology (STROBE) 13 statement is provided in the Supplement (see 'STROBE checklist').
Data sources
Study data were extracted from clinical and enterprise databases, including the Anesthesia Information Management Systems (AIMS), Research Patient Data Registry (RPDR), preadmission medication list (PAML), and Enterprise Performance Systems Inc. (EPSi) tool. The AIMS data warehouse contains data streamed directly from patient monitors, anaesthesia equipment, and the perioperative record. RPDR is a clinical database that compiles data from electronic health records at Partners HealthCare facilities for research purposes. The PAML is an electronic record of preadmission medications, which is first automatically populated with prescriptions from within the Partners HealthCare system, manually updated with information on outside medication during preoperative screening, and finally confirmed by the admitting nurse at the time of arrival on the day of surgery. EPSi is a financial tracking database used for internal cost tracking and value-based quality metrics, and contains encounter-level data on actual hospital costs, length of stay, and resource utilisation. 14e17 Data from these sources were standardised across all three sites during the study period and recorded in a common research registry.
Subject selection
The study cohort consisted of all adult patients undergoing surgical procedures under general endotracheal anaesthesia between January 1, 2007 and December 31, 2015, who were extubated at the end of the case. Cardiac surgery cases and patients with an ASA physical status classification system score of V or VI were not eligible. We further excluded patients who underwent any other surgical procedure within 4 weeks before the index case, or for whom data on the exposure variable (intraoperative opioid dose) and outcome variable (30-day readmission) were not available. A sub-cohort of 13 122 patients (8.5%) of the included cohort was previously analysed in a published study examining the effects of neuromuscular blocking agents on 30-day readmission after abdominal surgery. 18 
Exposure variable
The exposure variable was the total dose of opioid administered intraoperatively, defined as quintiles of i.v. morphine equivalents adjusted for lean body weight, according to the following method: the total dose of each opioid medication in milligrams was multiplied by its standard equianalgesic conversion ratio, 18, 19 and then divided by lean body weight. 20, 21 No adjustment for incomplete cross tolerance was performed given the short duration of intraoperative exposure. Both longacting opioids (morphine, hydromorphone, methadone, and meperidine) and short-acting opioids (fentanyl, sufentanil, and alfentanil) 22 were included in the primary exposure variable. Because of its unique pharmacokinetics and association with postoperative hyperalgesia, remifentanil dose was not included in the calculation of either total or short-acting opioid, but was rather adjusted for as an a priori defined covariate in the regression model.
Covariate data
All covariates were defined a priori based on literature review and physiological plausibility. The primary analysis was adjusted for baseline patient characteristics, including age, gender, BMI, ASA score, Charlson comorbidity index (CCI), 23 score for prediction of postoperative respiratory complications (SPORC), 14 admission type, source of admission for index surgery (home, nursing facility, or rehabilitation facility), and outpatient use of any opioid within 90 days before surgery. We adjusted for the characteristics related to surgical case complexity, including surgical service, emergent vs nonemergent status, procedure duration, intraoperative hypotension (time below mean arterial pressure of 55 mm Hg), and procedural severity score (PSS) for morbidity. 24 We further corrected for several factors related to anaesthesia care, including i.v. fluid dose, packed red-blood-cell transfusion, vasopressor dose equivalent, 24 age-adjusted effective dose of inhalational anaesthetics, 26, 28 use of neuraxial anaesthesia, neuromuscular blocking drug (NMBD) dose (expressed as multiples of NMBD dose needed to reduce the twitch height by 95%), 16, 22, 28, 29, 30 neostigmine dose, and remifentanil dose. A 
Outcomes
The pre-specified primary outcome was inpatient readmission to any facility in the Partners HealthCare network within 30 days of discharge from the initial surgical encounter. The charts of 200 randomly selected readmissions were manually reviewed to confirm the accuracy of the hospital-encounter reporting system, and demonstrated a complete agreement between the two methods. To test the validity of this endpoint, we compared the observed rate of readmission measured using this methodology to publically reported values for 30-day readmission of Medicare patients to any facility after undergoing hip or knee arthroplasty at MGH. We also tested the association between total intraoperative opioid dose and postoperative respiratory complications (PRCs) before discharge as a secondary outcome using a logistic-regression model, which included the same covariates as in the primary analysis and the previously validated composite endpoint comprised of reintubation, pulmonary oedema, respiratory failure, and pneumonia occurring within 7 days after surgery. 14 
Interactions with admission status and opioid class
We hypothesised that ambulatory patients and patients receiving a higher proportion of long-acting opioids would be at greater risk of opioid-associated readmission. We therefore performed planned analyses, including interaction terms for admission type (ambulatory vs non-ambulatory) and opioid class (fraction of long-acting over total opioid dose) to evaluate whether these factors modified the association between intraoperative opioid dose and 30-day readmission.
Exploratory analyses
We tested the post hoc hypotheses that ambulatory patients receiving high-dose opioids are at increased risk of early readmission, whilst patients who are admitted after surgery experience increased postoperative lengths of stay (PLOS). We examined the time to ambulatory readmission using the KruskaleWallis, ManneWhitney U, and c 2 tests as appropriate, and PLOS using a Cox proportional hazards model accounting for inpatient death.
To explore the association between intraoperative opioid dose and readmission diagnosis, we generated ICD-9/10 diagnostic categories for the 1000 most common primary and 500 most common secondary readmission diagnoses (see Supplementary material: 'list of diagnostic categories based on readmission diagnoses'), and independently tested the odds of developing a readmission diagnosis in each category using the same covariates as in the primary model.
To quantify the degree of inter-anaesthetist variation in opioid utilisation, we modelled the probability of each individual anaesthetist providing low to moderate (quintiles 1e3) vs high (quintiles 4e5) intraoperative opioid doses. All anaesthetists identified in 50 or more cases were included and adjustment for case mix was performed using a previously described method. 27 Variation according to primary surgeon was interrogated using the same analytical approach for comparison.
Sensitivity analyses
To assess the influence of model choice on the findings, we performed the following sensitivity analyses: multiple fractional polynomial analysis for adjustment of continuous covariates, time-to-event analysis with a Cox proportional hazards model accounting for death as a competing risk for readmission, mixed-effects modelling with anaesthetist as a random effect, patient-level (vs procedure-level) analysis retaining only the first surgery on record for each patient, and simplification of the model utilising a reduced number of covariates (retaining only age, gender, BMI, ASA, emergent status, admission type, preoperative opioid use, procedure duration, CCI, and PSS). To examine the potential influence of imputation of missing covariate data, we repeated the analysis in a subgroup of patients with no missing data. To assess the validity of our primary confounder control model, we also generated a probability score for the risk of 30-day postoperative readmission (independent of intraoperative opioid dose) using the covariates of the primary model, and then calculated the area under the curve (AUC) for comparison with published models. To further examine the utility of the predictions (i.e. the calibration, accuracy, and resolution), we estimated the Brier score. We performed sensitivity analyses using alternative methods of categorising preoperative opioid use [according to the World Health Organization (WHO) strength classifications 31 and total number of unique preoperative opioid medications, collapsed by generic drug entity] and a subgroup analysis of patients with no documented preoperative opioid use. The influence of postoperative opioid prescription practices was examined using an analogous approach. We also tested the effects of including remifentanil dose in the calculation of the primary exposure variable and analysing total opioid dose as a continuous outcome variable.
To assess the impact of procedural heterogeneity on the findings, we performed subgroup analyses in two more homogeneous International Statistical Classification of Diseases and Related Health Problems, 9th revision (ICD-9)-derived procedural subclasses (laparoscopic and non-laparoscopic ambulatory surgery), and performed a sensitivity analysis substituting work relative value units (RVUs) 32 for PSS as a measure of procedural complexity. To further examine the influence of time on the findings (in addition to controlling for procedure duration and year of surgery in the primary model), we performed sensitivity analyses, including interaction terms for opioid dose with procedure duration and opioid dose with year of surgery in the model. To account for potential bias arising from unobserved readmission to out-of-network hospitals, we performed sensitivity analyses, excluding patients residing more than 20 km from Boston based on home postal code (a distance previously shown to increase the probability of postoperative readmission to outside facilities) 32 and adjusting for differences in public vs private insurance coverage. 33 We also examined the effect of excluding patients discharged to nursing and rehabilitation facilities where minor postoperative conditions, such as pain, nausea, urinary retention, and dressing changes, might be treated without requiring hospital readmission. Because a small number of readmissions may be planned (e.g. scheduled postoperative admission for chemotherapy after bone marrow biopsy), we performed an analysis, including only readmissions clearly designated as urgent or emergent.
Statistical analysis
The results are presented as odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (CIs) and quintile 1 serving as the reference group for all comparisons. A two-tailed Pvalue of <0.05 was considered significant. All analyses were performed using Stata, College Station, TX (version 13.1). In the primary analysis and if not specified otherwise, we performed a multivariable logistic-regression analysis. Values for missing covariates were imputed using multiple imputation by chained equations utilising 10 burn-in rounds followed by a total of five final imputations using the Stata command 'mi impute'. To perform logistic-regression analysis in the imputed dataset, we used the Stata command 'mi estimate: logistic'. The 'esampvaryok' option was used for smaller subgroup analyses to allow for the expected increased variance across imputations in these smaller samples. Further information regarding study power, events per variable, and covariate categorisation is included in the Supplementary material (see 'Statistical analysis').
Results
A total of 153 902 of 174 990 recorded cases met the inclusion criteria of this study ( Fig. 1) . Table 1 provides the patient and perioperative characteristics of the study population by intraoperative opioid dose quintile. The total intraoperative opioid doses ranged from median (inter-quartile range), 8 (4e9) mg morphine equivalents in quintile 1 (Q1) to 32 (27e41) mg in quintile 5 (Q5).
Primary outcome: hospital readmission
A total of 11 953 (7.8%) of the patients were readmitted to the hospital within 30 days of discharge. Fig. 2A ). Adjusted event rates by opioid quintile in the general study population ranged from 7.5% (Q1) to 8.5% (Q5) (see Table 3 ). 
Secondary outcome: PRCs
Ambulatory surgery
We tested for effect modification by admission type (ambulatory surgery vs postoperatively hospitalised patients) based on the hypothesis that intraoperative opioid exposure would be more likely to influence post-discharge outcomes in this patient group. Ambulatory status was found to have a strong interaction with opioid-associated 30-day readmission (P<0.001). Based on this proof of effect modification, we performed subgroup analyses in the ambulatory surgery population. The characteristics of the ambulatory subgroup are shown in Supplementary eTable 2. The odds of 30-day hospital readmission rose steadily across ambulatory opioid dose quintiles (P for trend ¼0.046) with an OR of 1.75 (CI 1.46e2.10) in the highest vs lowest quintile, compared with 1.07 (CI 0.99e1.15) in non-ambulatory patients ( Fig. 2B and C) . Adjusted ambulatory readmission rates ranged from 3.5% (Q1) to 5.8% (Q5) (see Table 3 ).
Long-vs short-acting opioid classes
We observed a significant interaction between opioid class (long-vs short-acting opioid) and opioid dose for the primary outcome (P<0.001), where the odds of readmission were higher for long-compared with short-acting opioids in both ambulatory [Q5 long acting: OR 1. 
Exploratory analyses
We analysed the association between opioid dose and time from discharge to readmission amongst ambulatory patients.
Patients receiving higher doses of opioids during outpatient surgery were more likely to be readmitted early after discharge (P<0.001) (see Supplementary eFig. 1). We observed marked differences in the patterns of opioid administration amongst individual anaesthetists in our cohort, even after accounting for patient-and case-specific factors, which may influence anaesthetic requirements (Fig. 4A ). Some practitioners (left) consistently utilise low-to moderate-dose opioids in their practice, whilst others (right) routinely administer higher opioid doses. Even amongst patients undergoing highly similar surgical procedures, opioid dose varied significantly by anaesthetist. (Practice variation during common procedures in the entire study cohort and in the ambulatory subgroup is shown in Supplementary eFigs 2 and 3, respectively.) Compared with anaesthesia providers, more of the variation in intraoperative opioid use according to primary surgeon was explained by differences in case mix, rather than individual surgical practice. After adjustment for factors, such as procedure severity and duration, patient age and comorbidities, use of regional anaesthesia, etc., the differences between surgical providers across a range of specialties (Fig. 4B) were relatively small compared with the variation observed between anaesthesia providers. were calculated using standard equianalgesic conversion ratios 18, 19 with adjustment for lean body weight 21 and are reported in quintiles of i.v. morphine milligram equivalents. Logistic regression was performed using the model described in Supplementary eTable 1, which included adjustment for remifentanil exposure. IQR, inter-quartile range; OR, odds ratio. .001. Short-acting and long-acting equivalents were analysed separately using the logistic-regression model described in Supplementary eTable 1, which included adjustment for remifentanil exposure. Total short-acting and long-acting doses were calculated using standard equianalgesic conversion ratios 18, 19 with adjustment for lean body weight, 21 and are reported in quintiles of fentanyl and hydromorphone equivalents, respectively. IQR, inter-quartile range; OR, odds ratio.
Sensitivity analyses
Multiple fractional polynomial, Cox proportional hazard, mixed-effect, patient-level, and simplified logistic-regression models yielded results similar to the primary analysis (see Supplementary eTable 34e36 The Brier score of this model was 0.068, which reflects an acceptable degree of accuracy, and can be interpreted as the mean squared difference between predictions and actual events.
The predictions from the model were diverse and ranged from 0.05% to 86.2%, reflecting good variability in the predicted risk. Additionally, the predictions were well calibrated and closely approximated actual risk across a range of values (Brier reliability ¼0.0002).
Hospital records, including prescription data and information obtained from patient interview, revealed that 19.1% of patients were recorded as using one or more opioid medication within 90 days before surgery. Within this window, 5.8% were recorded as using two or more, and 1.7% had records of three or more opioids on file. Using the WHO opioid strength classification, 6.7% and 12.3% of patients used 'weak' and 'strong' opioids, respectively. The reported use of any preoperative opioid medication did not modify the association between intraoperative opioid dose and readmission (interaction term P¼0. 45) , and controlling for the number and strength of preoperative opioid medications also did not modify the association (P¼0.89 and P¼0.64, respectively) (see Supplementary eTable 6a and b). Excluding all patients with documented preoperative opioid use also confirmed the independent association between intraoperative opioid dose and postoperative readmission within an opioid naïve subgroup (see Supplementary eTable 6c). Using the same method of classification, 49% of patients received no postoperative opioid prescription, 5% received a prescription for a weak opioid, and 46% received a strong opioid. This distribution was similar within the ambulatory subgroup (37%, 8%, and 55%, respectively). A high number of opioid compounds prescribed after surgery was a predictor of a higher 30- Sensitivity analyses assessing potential confounding factors related to the ascertainment of the readmission outcome did not identify geographic distance to home, discharge destination, insurance status, or the influence of planned readmissions as important sources of bias (see Supplementary eTable 4). A full presentation of sensitivity analyses is included in the Supplementary material (see 'Sensitivity analyses').
Discussion
In a pre-specified analysis of registry data from 153 902 noncardiac surgical procedures performed under general anaesthesia, we observed substantial variability across individual anaesthesia providers in the use of opioids during surgery. We demonstrate that this variability is largely driven by the individual practice of the anaesthetist (rather than patient-, surgeon-, or procedure-related characteristics) and is independently associated with the risk of postoperative readmission.
This association was particularly significant in the ambulatory surgery population, with a continuous increase in the adjusted rate of readmission across the opioid-dosing spectrum. This supports the view that providers involved in ambulatory surgery should implement opioid-sparing strategies, such as multimodal analgesia and minimally invasive surgical techniques.
In contrast to non-ambulatory procedures, in which the majority of postoperative readmissions have been attributed to surgical complications, 37 readmission within 30 days of outpatient surgery is very rarely because of surgical factors. 38, 39 Patients who received high doses of opioids during ambulatory surgery were readmitted significantly earlier and their odds for readmission during the first 48 hours were almost three-fold increased. A mechanistic link between intraoperative opioid dose and readmission after outpatient surgery is pharmacologically plausible, as the side-effects of intraoperatively administered medications should be more relevant in the early recovery period. Indeed, we observed that readmission occurred significantly earlier and more often in ambulatory patients who received higher doses of opioids as part of their anaesthetic, whilst admitted patients receiving high intraoperative opioid doses experienced increases in PLOS. Exploratory analyses showed that diagnoses of surgical site infection were significantly increased in patients readmitted after receiving high opioid doses during surgery. In contrast, intraoperative opioid dose was not associated with noninfectious wound-related complications (e.g. haematoma, wound dehiscence, and hardware malfunction). Chronic opioid use has previously been associated with an increase in the risk of postoperative infection, 7 and the immunosuppressive potential of opioid medications may have clinical relevance in the perioperative setting. 41 The association between high-dose intraoperative opioid exposure and readmission for surgical site infection, observed in an exploratory analysis, needs to be further evaluated in a prospective study with low risk of bias in ambulatory surgery patients.
Compared with preoperative opioid use, which has also been associated with hospital readmission, 9 intraoperative opioid administration is almost routine (97% in our cohort), in many cases involves higher doses than those given on an outpatient basis, is controlled by the physician rather than the patient, and is a practice that may be more amenable to evidence-based change. Intraoperative opioid administration is also captured precisely in the anaesthetic record, in contrast with outpatient opioid use, which is difficult to discriminate based on prescription data and patient report alone. 41e43 Our findings support the relevance of the association between opioids and adverse postoperative outcomes, 9 and highlight the importance of the intraoperative component of perioperative opioid exposure with regard to such outcomes. Our study derives strength from the size and quality of the research database, which contains standardised, high-density perioperative data from a large healthcare network. These include detailed information on the primary exposure variable (intraoperative opioid dose, and important information on preoperative patient characteristics, case-specific surgical and anaesthetic factors, and complete records from postoperative encounters). The resulting confounder control model (independent of opioid dose) compares favourably with previously published prediction tools for modelling the risk of postoperative readmission. Our findings must be interpreted in the context of the study's limitations, which include the retrospective nature of the design and the use of billing, prescription, and other administrative data sets, which include missing values for some cases. Preoperative opioid use is an important source of potential confounding, and is inherently challenging to capture and quantify. The preoperative medication list from which we derived this information includes both prescription data and patient-reported medications, and is confirmed by the preoperative nurse during the intake interview on the day of surgery. We found that the association between opioid dose and readmission remained significant in an analysis of patients believed to be opioid naïve. Further controlling for the strength and number of patients' preoperative opioid medications also did not modify the effect of intraoperative opioid dose on readmission rate.
Readmission to out-of-network facilities represents another potential source of bias related to ascertainment of the outcome variable. However, data on readmission were collected from all facilities in the greater Partners HealthCare network and were comparable with published rates for Medicare patients undergoing surgery at our institution during the same time period (which include those readmitted to other hospitals), 45 confirming that the number of uncaptured readmissions was relatively small. A series of sensitivity analyses focused on factors influencing unobserved readmission also did not indicate this as a significant source of bias. This diversity of the primary study cohort adds to the generalisability of the findings, but it raises the question as to whether there might be unidentified confounding variables related to procedure type or indication bias (certain A small number of practitioners (left) consistently utilise conservative opioid doses during surgery, whilst another group (right) regularly administer higher doses. A similar distribution is observed both before (grey circles) and after (red circles) propensitymatched adjustment for factors that may influence opioid administration (including procedure duration, procedural severity score, preoperative opioid use, admission status, surgical service, BMI, weight, depth of anaesthesia, and use of neuraxial techniques). A parallel analysis of variation according to (B) primary surgeon indicates that much of the heterogeneity across surgical practice is related to differences in case mix. After adjustment for the same patient-and case-specific factors, the range of variability attributable to the influence of the surgeon (60.4þ/À6.0%) is relatively small compared with that of the individual anaesthetist (59.1þ/À11.6%).
procedures 'requiring' higher opioid doses). We therefore conducted sensitivity analyses in two procedure-entity-based subgroups of patients (laparoscopic and non-laparoscopic outpatient procedures). The association between intraoperative opioid dose and 30-day readmission remained stable within these more homogeneous patient populations. Using work RVUs and clustering by anaesthetist to further account for differences in procedural complexity, case mix, and individual practice did not alter the result.
Clinical implications
In this study, an association between intraoperative opioid dose and the risk of postoperative readmission was observed. The assumption of a pharmacologically plausible causeeeffect relationship is based on the following observations: first, the association between opioid dose and 30-day readmission is dose dependent and is modified by pharmacological class (short vs long acting). Second, opioid-associated readmissions after ambulatory surgery occurred early, most frequently during the first 48 hours after discharge. Third, there was substantial provider variability in opioid dosing for the same surgical procedure, unexplained by patient or procedural factors. Finally, we achieved robust confounder control for hospital readmission: the C-statistic and the Brier score indicate that model discrimination is adequate, the predictions from the model were diverse, and the predictions were well calibrated with actual risk.
In ambulatory populations, where this association is particularly strong, long-acting doses above the equivalent of approximately 0.4 mg i.v. hydromorphone and short-acting doses on the order of 100 mg fentanyl were significantly associated with readmission. Doses above this range may be viewed as increasing the risks associated with home discharge after outpatient surgery (specifically the risk of hospital readmission) and may help identify patients prone to delayed complications, even if the short-term effects of opioid administration (e.g. sedation, respiratory depression, and nausea) appear resolved in the immediate postoperative period.
Whilst these approximate thresholds are based on post hoc analysis of our data, such estimates may be useful in the design of prospective trials and the implementation of local quality-improvement efforts aimed at limiting perioperative opioid use. A recent initiative at our institution based on parallel data for intraoperative use of neuromuscular blocking agent dosing recently demonstrated not only an improvement of desirable behaviours, but also a decrease in PRC rates (manuscript in preparation).
The high degree of observed variation in the use of intraoperative opioids amongst anaesthetists underscores the need of outcome-oriented evidence-based guidelines in this arena. Our data support the view that conservative intraoperative opioid-dosing standards, particularly in outpatient surgery, may yield improved postoperative outcomes and lend credence to efforts aimed at developing opioid-sparing anaesthetic protocols. 46 
